Covidien debuts new hernia mesh implant; Integra gains 510(k) for foot surgery-related titanium bone wedges;

@FierceMedDev: Add debt restructuring to Quest Diagnostics' numerous moves to improve things. Story | Follow @FierceMedDev

@MarkHFierce: Philips ventilator recall gets slapped with the FDA's Class I recall status--its most serious designation. More | Follow @MarkHFierce

@MichaelGFierce: NeuroDerm preps for Parkinson's patch PhII trial. Read in FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Roche gets glowing reviews from FDA panel for frontline HPV test. Article | Follow @EmilyWFierce

> Covidien ($COV) said it is launching a new mesh product designed for surgical laparoscopic and open ventral hernia repairs. News release

> Bacterin International is rolling out a new allograft implant designed for multilevel spine procedures and deformity patients. Item

> Surefire Medical gained both a 510(k) and CE mark for a new line of guiding catheters designed for radioembolization and chemoembolization procedures. News release

> Medtronic ($MDT) is looking for runners with medical device implants such as pacemakers, spinal or neurological devices to participate in a marathon coming up in October. Story

> Integra LifeSciences ($IART) won 510(k) clearance for titanium bone wedges used to repair foot bone fractures. Story

Biotech News

@FierceBiotech: Sage snags $38M from A-list VCs to bankroll its seizure drugs. More | Follow @FierceBiotech

@JohnCFierce: Circassia's record-busting $332M IPO inspires hopes of U.K. renaissance. News | Follow @JohnCFierce

@DamianFierce: Vectura bags respiratory biotech Activaero for $181M. Story | Follow @DamianFierce

@EmilyMFierce: Despite progress, tuberculosis persists in West European cities. Piece via Reuters | Follow @EmilyMFierce

> GlaxoSmithKline maps a route to regulators with positive PhIII asthma data. Article

> Tesaro pays $17M to team with AnaptysBio on cancer immunotherapies. More

Pharma News

@FiercePharma: Yesterday's top-read special report: The top 10 pharma companies by 2013 revenue. Read | Follow @FiercePharma

@TracyStaton: Uh-oh for Merck animal health: Hundreds more Zilmax-fed cattle died than Merck reported to FDA. Story via Reuters | Follow @TracyStaton

@EricPFierce: Sun Pharma plant joins FDA village of the banned. Story via FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Missed yesterday's issue of FiercePharmaMarketingGot you covered | Follow @CarlyHFierce

> Pfizer's billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics. Article

> High court dashes Actelion's hopes for $407M reprieve in Tracleer case. More

Pharma Manufacturing News

> CMO born from $2.6 billion merger comes on the scene as DPx. Story

> Sun Pharma plant joins the FDA list of banned Indian facilities. News

> FDA says Indian drugmaker made up data for API tests. Piece

> Bayer expands German plants as it preps for new hemophilia treatments. More

> Hikma hits the jackpot with doxycycline shortage. Coverage

> Pharma cargo theft takes new spike. Brief

Vaccines News

> Daiichi misses H5N1 vaccine production goal after low yields slash output. Story

> Analysts offer mixed reactions to Pfizer's Prevnar 13 data close-up. Article

> Northwest Bio, NewLink proceed with cancer vax trials to mixed reviews. News

> ImmusanT waits on early clinical data for its celiac disease vaccine. Story

> Study: Vaccinating diabetics against flu cuts risk of death by 28%. Article

> U.K. mulls adopting a 2-dose model for HPV vaccination. Brief

> Editor's Note: A story in Wednesday's issue of FierceMedicalDevices attributed some comments to a spokeswoman for PowerVision. The comments originated with the company's CEO, Barry Cheskin. A separate story on Hospira in the same edition was updated to more clearly state the compliance history of its Rocky Mount, NC, and Austin, TX, plants. Rocky Mount faced a previous warning letter but not the Austin operation.

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.